Christophe Hotermans, M.D., Ph.D., has joined Akcea Inc. as senior vice president of global medical affairs where he will lead and evolve the execution of medical strategies, activities and operations worldwide in collaboration with executive management.
 
“We are pleased to welcome Christophe to our leadership team and believe that his clinical experience and his experience leading the medical affairs function, including KOL engagement, medical communications and launch readiness, will be invaluable to the team,” said Dr. William Andrews, chief medical officer at Akcea. “His expertise in developing global medical strategies in specialty care and rare diseases will be a great asset and will provide strategic expertise as we continue to successfully execute on our two commercial launches across the world.”
 
Hotermans’ career spans more than 20 years, including over 12 years in the biotechnology industry, where he held various roles in drug safety, International, U.S. and Global medical affairs, and the launch of five products across multiple therapeutic areas in specialty care and rare diseases. Prior to joining Akcea, Hotermans served at Biogen in various roles, most recently as vice president and head of U.S. medical, where he was responsible for the U.S. medical strategy and execution across all therapeutic areas, including multiple sclerosis, Alzheimer’s disease, movement disorders and amyotrophic lateral sclerosis. Prior to Biogen, he was chief of the neurology clinic at the University of Liège in Belgium.
 
“It is an exciting time to join Akcea as the company makes important advances of multiple promising pipeline products and progress with the rollout of TEGSEDI and WAYLIVRA globally,” said Hotermans. “I look forward to working with executive leadership, the medical affairs teams and engaging with doctors to bring transformational medicines to patients in need who are living with serious and rare diseases.”
 
Hotermans received his medical degree and Ph.D. in medical sciences from The University of Liège, Belgium. He is an active member of The European Neurological Society, American Academy of Neurology and Medical Affairs Professional Society (MAPS) and has also authored multiple peer-reviewed journal publications.